FDA Approval Targets Rare Kidney Disease - Top_Thought_Leaders - MDSpire

FDA Approval Targets Rare Kidney Disease

Phase 3 data showed greater proteinuria reduction vs irbesartan, with similar tolerability and a 1.1 mL/min/1.73 m² difference in estimated glomerular filtration rate at 108 weeks.

  • By

  • Kathryn Wighton

  • April 14, 2026

  • 2 min

Share

Top Thought Leaders in General Medicine

Brief introduction explaining scope and methodology.

Original Source(s)

FDA Approval Targets Rare Kidney Disease

  • by Kathryn Wighton

  • April 14, 2026

Related Content

Combination Therapy Shows Potential in Psoriasis, Obesity

Researchers assess whether adding tirzepatide to ixekizumab affects skin and weight outcomes in adults with moderate to severe plaque psoriasis.

Development and validation of a prediction model for 1-year all-cause rehospitalisation after discharge in patients with heart failure with preserved ejection fraction based on the systemic immune-inflammation index

FDA Monthly Preview: Key June Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.